Eric Lorraine, DO
Family Medicine · Endwell, NYNPI 1801114285
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (41.0%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Novo Nordisk at 24.9% of the total. Reporting peaked in 2024 at $4,033 and has fallen 88.3% since, to $471 in 2025. Among family medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 217 payments — averaging $42.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Eli Lilly$2K
- AstraZeneca$2K
- AbbVie$1K
- Lilly USA, LLC$285
- Pfizer$274
- plus $1K from 24 others
Across 172 payments — averaging $4278.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$221K
- GSK$189K
- Eli Lilly$118K
- Currax Pharmaceuticals LLC$97K
- AstraZeneca$42K
- Sanofi Pasteur Inc.$39K
- plus $29K from 1 others
What the payments were for
- Consulting fees$1,74019%
- Travel & lodging$3,75641%
- Food & beverage$3,65740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 35 | $2,275 |
| Eli Lilly | 4 | $2,220 |
| AstraZeneca | 13 | $1,891 |
| AbbVie(2 entities) | 56 | $1,195 |
| Lilly USA, LLC | 17 | $285 |
| Pfizer | 36 | $274 |
| Stryker | 1 | $139 |
| Amgen | 7 | $106 |
| Boehringer Ingelheim | 6 | $100 |
| GSK | 6 | $87 |
| Phathom Pharmaceuticals, Inc. | 4 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| Abbott | 3 | $47 |
| Edwards Lifesciences | 1 | $46 |
| Irhythm Technologies, Inc. | 1 | $38 |
| Corium, LLC | 3 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Corcept Therapeutics | 2 | $30 |
| Exact Sciences | 2 | $29 |
| Novartis | 2 | $26 |
| Johnson & Johnson | 2 | $26 |
| Verona Pharma, Inc. | 1 | $24 |
| Merck | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Gilead | 1 | $14 |
| Si-bone, Inc. | 2 | $14 |
| Bayer | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Neuronetics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MAKO$139
How this compares
$9,153 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 112 | $145,421 |
| OzempicSemaglutide | 94 | $121,327 |
| JardianceEmpagliflozin | 84 | $112,710 |
| TrulicityDulaglutide | 48 | $72,833 |
| JanuviaSitagliptin Phosphate | 43 | $65,112 |
| MounjaroTirzepatide | 35 | $52,816 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $41,734 |
| FarxigaDapagliflozin Propanediol | 21 | $32,040 |
| MyrbetriqMirabegron | 12 | $13,002 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $10,820 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $10,411 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 18 | $8,319 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 52 | $8,226 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $6,614 |
| Atorvastatin Calcium | 582 | $6,238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $274 | $150,737125 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $285 | $125,64983 claims |
| Novo NordiskOzempic | $2,275 | $121,32794 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $100 | $121,029102 claims |
| MerckJanuvia | $23 | $65,11243 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $87 | $58,760105 claims |
| AstraZenecaFarxiga, Symbicort | $1,891 | $35,90332 claims |
| AbbVieSynthroid | $1,195 | $1,98117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in Endwell
- Louis BonavitaEast Syracuse$674K
- Martin MahoneyBuffalo$520K
- Scott BrehautClinton$514K
- David St PeterSaratoga Springs$395K
- Matthew PabisNew York$222K
- Rajveer SachdevPomona$211K
- Eric SchnakenbergHalfmoon$190K
- James NorthGlens Falls$186K
- Eric BatesNew York$171K
- Alexander BlinskiNew York$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.